APW
CRSP icon

Atlantic Private Wealth’s CRISPR Therapeutics CRSP Stock Holding History

Atlantic Private Wealth’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$714 Hold
15
– – ﹤0.01% 256
2025
Q4 		$787 Hold
15
– – ﹤0.01% 276
2025
Q3 		$972 Hold
15
– – ﹤0.01% 229
2025
Q2 		$730 Hold
15
– – ﹤0.01% 229
2025
Q1 		$510 Buy
+15
New +$636 ﹤0.01% 204
2024
Q4 		– Sell
-15
Closed -$704 – 198
2024
Q3 		$704 Hold
15
– – ﹤0.01% 179
2024
Q2 		$810 Hold
15
– – ﹤0.01% 99
2024
Q1 		$1.02K Buy
+15
New +$1.07K ﹤0.01% 104

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Atlantic Private Wealth's CRSP Position: Q1 2026 in Review

Atlantic Private Wealth held its CRISPR Therapeutics (CRSP) position steady in Q1 2026 at 15 shares worth $714. The position accounts for ﹤0.01% of the portfolio, ranked #256.

Atlantic Private Wealth first reported a position in CRSP in Q1 2024 and has held it in 8 quarters since. The position peaked at $1.02K in Q1 2024. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Atlantic Private Wealth held 15 shares of CRISPR Therapeutics worth $714 as of Q1 2026.
  • Atlantic Private Wealth left its CRISPR Therapeutics share count unchanged in Q1 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Atlantic Private Wealth's portfolio in Q1 2026, its #256 holding.
  • Atlantic Private Wealth first reported a position in CRISPR Therapeutics in Q1 2024 and has held it in 8 quarters since.
  • Atlantic Private Wealth's CRISPR Therapeutics position peaked at $1.02K in Q1 2024.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Atlantic Private Wealth's 13F filing for Q1 2026, filed 8 May 2026.